Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

PARIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop ...

28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine ... In countries across the Nordic and Baltic regions, prostate cancer is one of the most common cancers among men with ...